ImageneBio is a San Diego biopharmaceutical company developing IMG-007, an experimental antibody for autoimmune and inflammatory diseases. IMA reports earnings on Wed, Nov 11, 2026.
Earnings
Earnings calendar →Analyst Ratings & Price Targets
Analyst Ratings →| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Aug 21 | HC Wainwright & Co. | Initiated | Buy |
Seasonality
How IMA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.
Whale Options Flow
90DNo whale options trades in IMA in the last 90 days.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether IMA is in one of them and how their past IMA trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered IMA in an article yet. Here's the latest on the wider market.
About ImageneBio
ImageneBio is a biopharmaceutical company based in San Diego, California, that is developing treatments for immunological, autoimmune and inflammatory diseases. Its main candidate, IMG-007, is an experimental antibody that targets the OX40 receptor on activated T cells. The company is still in clinical trials and is first testing the candidate in atopic dermatitis, a common form of eczema, with plans to study other conditions. Its intended patients are people with these diseases, and its treatments would be prescribed by physicians.
- Headquarters
- San Diego, CA